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 Abstract/summary 
In this issue of Cancer Cell, Ge et al. show that overexpression of the oncoprotein iASPP in cancer 
cells provokes NRF2-mediated induction of cytoprotective genes because it logjams the ubiquitin 
ligase substrate adaptor function of KEAP1 by virtue of the fact it possesses a novel DLT-
containing KEAP1-interaction motif. 
 
 
Main text 
The inhibitor of apoptosis stimulating protein of p53 (iASPP) is regarded as an oncoprotein 
because it antagonizes the ability of p53 to induce pro-apoptotic genes (see Lu et al. (2013) and 
papers cited therein). Since p53 regulates expression of antioxidant enzymes, such as catalase, 
GPX1 and SOD2, it might be anticipated that its inhibition upon overexpression of iASPP would 
increase the intracellular levels of reactive oxygen species (ROS). Contrary to such expectations, 
Ying Hu and colleagues discovered that ectopic overexpression of iASPP in cancer cell lines 
decreased levels of ROS and increased the ratio of reduced glutathione (GSH) to oxidized 
glutathione (GSSG), in a p53-independent manner, whereas knockdown of iASPP increased ROS 
levels and decreased the ratio of GSH to GSSG (Ge et al., 2017).  
 In an attempt to understand how iASPP decreased level of intracellular ROS and increased 
antioxidant capacity, Ge et al. considered that it might activate the cap’n’collar (CNC) basic-
region leucine zipper (bZIP) transcription factor NF-E2 p45-related factor 2 (NRF2, encoded by 
NFE2L2) because NRF2 is a master regulator of redox homeostasis. In response to oxidative 
stressors, NRF2 induces genes involved in the synthesis and maintenance of both glutathione- and 
thioredoxin-based antioxidant systems as well as the detoxification of drugs. Consistent with this 
proposal, these workers found that knockdown of iASPP in human bladder T24 carcinoma cells 
decreased expression of endogenous NRF2-target genes whilst overexpression of iASPP induced 
 NRF2-regulated genes. Moreover, the increase in NRF2-target gene expression affected by iASPP 
was accompanied by an increase in the abundance of NRF2 protein, but not NRF2 mRNA, and 
was therefore attributed to inhibition of degradation of the CNC-bZIP transcription factor (Ge et 
al., 2017). 
To test whether iASPP might interfere with NRF2 protein turnover directed by Kelch-like 
ECH-associated protein 1 (KEAP1) and the cullin-3 (CUL3)-RING ubiquitin ligase CRLKEAP1, 
Ge et al. demonstrated iASPP can physically interact with KEAP1 and in so doing blocks binding 
of NRF2 to KEAP1. These experiments revealed that a DLT motif in iASPP, between amino acids 
239 and 241, is required for its interaction with the Kelch-repeat domain (also called DGR) of 
KEAP1. They then provided experimental evidence that the interaction of iASPP with KEAP1 
prevented CRLKEAP1 from ubiquitylating NRF2, thereby stabilizing the CNC-bZIP transcription 
factor and enabling induction of its target genes (Ge et al., 2017). 
It is well known that KEAP1 is a CUL3 substrate adaptor and that NRF2 binds to the two 
Kelch-repeat domains in the dimeric KEAP1 protein through two separate motifs in its N-terminal 
Neh2 domain, designated DLG and ETGE (Figure 1A). The ETGE motif binds to KEAP1 with a 
relatively high affinity (dissociation constant approx. 10 nM), whereas the DLG motif binds to 
KEAP1 with lower affinity (dissociation constant approx. 3200 nM) (Fukutomi et al., 2014). 
Importantly, both motifs are required for CRLKEAP1 to ubiquitylate NRF2 (McMahon et al., 2006). 
Besides NRF2, other proteins can bind KEAP1. Ben Major and colleagues identified a significant 
number of proteins with ETGE or related motifs that bind KEAP1 (Hast et al. 2013) (Figure 1B), 
a finding that suggests KEAP1 represents the hub of a network of pathways that links various 
agonists to NRF2-mediated induction of antioxidant and detoxication genes. In particular, NRF2 
activity can be increased by some of these ETGE-containing proteins, when they are 
overexpressed or phosphorylated, because they prevent NRF2 from docking simultaneously 
through both its DLG and ETGE motifs onto dimeric KEAP1 (Figure 1C); it is envisaged that 
 the ETGE-containing proteins out-compete the low-affinity DLG motif of NRF2 for binding to 
KEAP1. 
The best studied example of cross-talk through the KEAP1 signaling hub is provided by 
p62/sequestosome 1 (SQSTM1). During nutritional stimuli, the STGE motif of p62/SQSTM1 is 
phosphorylated by mechanistic target of rapamycin complex 1 (mTORC1), whereupon its affinity 
for KEAP1 is increased, resulting in formation of a p62/SQSTM1-KEAP1 complex that is 
removed by selective autophagy, thereby allowing induction of NRF2-target genes (Ichimura et 
al., 2013). Another example, which shares some parallels with iASPP, is that of the ETGE-
containing protein dipeptidyl peptidase 3 (DPP3), which when overexpressed in squamous lung 
or breast cancer cells stimulates an increase in NRF2 activity; notably, the interaction between 
DPP3 and KEAP1 is bolstered by treatment with H2O2 (Hast et al., 2013; Lu et al., 2017). Further 
examples of ETGE-containing proteins that bind KEAP1 and possibly influence NRF2 activity 
include the breast cancer protein PALB2 (partner and localizer of BRCA2) and the DNA helicase 
minichromosome maintenance 3 (MCM3), but as both PALB2 and MCM3 are ubiquitylated by 
CRLKEAP1 (Orthwein et al.,2015; Mulvaney et al., 2016) their effects on NRF2-target gene 
expression may be short-lived. 
A remarkable feature of the binding of iASPP to KEAP1 is that it involves a DLT motif. 
This was unexpected because all proteins identified to date that bind KEAP1 possess a ‘high-
affinity’ ETGE motif, or closely related sequence, and none contain only a ‘low-affinity’ DLG 
motif (Figure 1B). It is therefore unclear how the DLT motif in iASPP can compete with NRF2 
for binding to KEAP1. It appears likely that the DLT motif in iASPP forms a novel interaction 
structure and that flanking sequences increase the ability of iASPP to bind to KEAP1. This notion 
is supported by the fact that in cancer (particularly in non-small cell lung carcinoma), many 
somatic mutations in NFE2L2 that result in NRF2 gain-of-function produce amino acid 
substitutions in the Neh2 domain between residues 23 and 43, suggesting that amino acids other 
 than the DLG tripeptide contribute to binding of this motif to KEAP1 (Fukutomi et al., 2014). 
Indeed, Fukutomi et al. (2014) pointed out that hydrophobic interactions are particularly important 
in the binding of DLG-containing peptides to the Kelch-repeat domain of KEAP1. On the basis 
of this argument, residues in iASPP, such as R244 may contribute to binding by the DLT motif to 
KEAP1, as will hydrophobic residues (Figure 1B). Provocatively, the DLT motif in iASPP lies 
between two PP dipeptide sequences (amino acids 232/233 and 246/247) that may impart a unique 
fold on this region of iASPP, but the significance of these two PP residues is unknown. 
The fact that iASPP can bind KEAP1 raises interesting questions about its relationship 
with other proteins engaged in the KEAP1 signaling hub. Firstly, since p62/SQSTM1 is capable 
of sequestering KEAP1 for autophagy, can it similarly direct iASPP for autophagy when iASPP 
is bound to KEAP1? Secondly, since iASPP inhibits CRLKEAP1 ubiquitylation of NRF2, does it 
also inhibit CRLKEAP1 ubiquitylation of MCM3, PALB2 and PGAM5? Thirdly, what biological 
implications does the binding of iASPP to KEAP1 have for the association of other proteins that 
may not be ubiquitylated by CRLKEAP1? 
Having described the mechanism by which iASPP positively controls NRF2, Ge at el 
(2017) showed that knockdown of iASPP in xenograft models resulted in a reduction in NRF2 
protein, and expression of its target genes, along with a decrease in tumor weight and size. 
Moreover, knockdown of iASPP in xenograft models increased the sensitivity of the tumors to 
the chemotherapeutic drug 5-fluorouracil. 
In summary, the work of Ge et al (2017) suggests that iASPP co-opts NRF2 to support an 
oncogenic program that increases cell proliferation and drug resistance. In particular, iASPP 
delegates the task of augmenting antioxidant defenses and drug detoxification to NRF2. It is also 
possible that NRF2 aids iASPP-directed oncogenesis by reprograming metabolism. Further work 
is required to establish the extent to which iASPP contributes to NRF2 activity in normal and 
 cancer tissue, and the extent to which the overexpression of iASPP in tumors perturbs the KEAP1 
stress signaling network. 
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 Figure 1. Identity of members of the KEAP1 stress signaling hub 
 
(A) The cartoon illustrates the two-site tethering of NRF2, through its DLG and ETGE motifs, 
across two Kelch-repeat domains contained within the KEAP1 dimer. Both the DLG and ETGE 
motifs have to lock onto the KEAP1 dimer for NRF2 protein ubiquitylation, and subsequent 
proteasomal degradation, to proceed (McMahon et al., 2006).  
(B) Amino acid sequences in human NRF2 that encompass the DLG and ETGE motifs (shown 
underlined at the top) have been aligned with sequences of proteins that interact with KEAP1. The 
alignment is based solely on the presence of DLG-related, ETGE, DTGE, ESGE and STGE 
sequences within proteins reported to bind KEAP1. The amino acids in NRF2 that are shown as 
white letters on a black background are those that have been reported to have been changed by 
somatic NFE2L2 mutations in cancer and are therefore presumed to be necessary for its interaction 
with KEAP1 (Fukutomi et al., 2014). Amino acids in the other KEAP1-binding proteins that align 
with these residues in NRF2 are depicted in the same way. In all cases, data from human proteins 
are presented.  
(C) Cartoon showing stimuli that are postulated to enhance the binding of iASPP, p62/SQSTM1, 
DPP3 and PALB2 for KEAP1. iASPP is overexpressed during oncogenesis (Ge et al., 2017). 
p62/SQSTM1 is phosphorylated at a STGE motif by mTORC1 in response to nutrients (Ichimura 
et al., 2013). DPP3 is overexpressed during oncogenesis and its interaction with KEAP1 is also 
increased by oxidative stress (Lu et al., 2017). PALB2 is involved in DNA double-strand break 
repair. Although forced overexpression of PALB2 can activate NRF2 (Ma et al., 2012), it is 
unclear whether this happens during stimulation of DNA damage because PALB2 is ubiquitylated 
by CRLKEAP1 (Orthwein et al., 2015); this uncertainty is indicated by a question mark. Through 
their KEAP1-binding activity, iASPP, p62/SQSTM1, DPP3 and [possibly] PALB2 can each 
stabilize de novo synthesized NRF2 protein. In turn, the ensuing nuclear accumulation of NRF2 
induces genes, including those that increase antioxidant status (e.g. SLC7A11, GCLC, GCLM, 
 GPX2, HMOX1, PRDX1, SRXN1, TXN1 and TXNRD1), increase detoxification capacity (e.g. 
AKR1B10, AKR1C1, AKR1C2, AKR1C3 and NQO1) and reprogram metabolism (e.g. G6PD, 
IDH1, ME1, PGD, TALDO1 and TKT). 
(Image created by Rumen V. Kostov, University of Dundee). 
 
 
